Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002250 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002250: Completed Phase 1 study, sponsored by Genentech.
NCT00002250 is a Phase 1 study that has completed, run by Genentech. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002250, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of HIV infection.
Interventions
- DRUG CD4-IgG
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
What the finished NCT00002250 record still lists
NCT00002250 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which CD4-IgG is the first listed.
NCT00002250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002250 about?
NCT00002250 is a clinical study titled "A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura". To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of HIV infection.
What is the current status of trial NCT00002250?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002250?
The interventions under investigation include: CD4-IgG (DRUG).
Who is sponsoring clinical trial NCT00002250?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.